Is Cytokinetics Incorporated (CYTK) a Keeper?

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Cytokinetics Incorporated (NASDAQ:CYTK) went down by -43.25% from its latest closing price compared to the recent 1-year high of $30.14. The company’s stock price has collected 27.74% of gains in the last five trading sessions. Press Release reported 1 hour ago that Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Is It Worth Investing in Cytokinetics Incorporated (NASDAQ :CYTK) Right Now?

Plus, the 36-month beta value for CYTK is at 1.38. Opinions of the stock are interesting as 8 analysts out of 8 who provided ratings for Cytokinetics Incorporated declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored



The average price from analysts is $41.13, which is $24.56 above the current price. CYTK currently public float of 69.94M and currently shorts hold a 10.26% ratio of that float. Today, the average trading volume of CYTK was 1.11M shares.

CYTK’s Market Performance

CYTK stocks went up by 27.74% for the week, with a monthly jump of 22.91% and a quarterly performance of 5.88%, while its annual performance rate touched 148.25%. The volatility ratio for the week stands at 9.79% while the volatility levels for the past 30 days are set at 6.83% for Cytokinetics Incorporated. The simple moving average for the period of the last 20 days is -32.27% for CYTK stocks with a simple moving average of -14.30% for the last 200 days.

Analysts’ Opinion of CYTK

Many brokerage firms have already submitted their reports for CYTK stocks, with Raymond James repeating the rating for CYTK by listing it as a “Strong Buy.” The predicted price for CYTK in the upcoming period, according to Raymond James is $39 based on the research report published on July 10th of the current year 2020.

Mizuho, on the other hand, stated in their research note that they expect to see CYTK reach a price target of $31. The rating they have provided for CYTK stocks is “Buy” according to the report published on May 05th, 2020.

Morgan Stanley gave a rating of “Overweight” to CYTK, setting the target price at $25 in the report published on April 09th of the current year.

CYTK Trading at -31.95% from the 50-Day Moving Average

After a stumble in the market that brought CYTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.93% of loss for the given period.

Volatility was left at 6.83%, however, over the last 30 days, the volatility rate increased by 9.79%, as shares sank -30.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.01% lower at present.

During the last 5 trading sessions, CYTK fell by -30.22%, which changed the moving average for the period of 200-days by +54.84% in comparison to the 20-day moving average, which settled at $22.83. In addition, Cytokinetics Incorporated saw 160.65% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CYTK starting from PARSHALL B LYNNE, who sale 50,311 shares at the price of $30.00 back on Oct 05. After this action, PARSHALL B LYNNE now owns 0 shares of Cytokinetics Incorporated, valued at $1,509,330 using the latest closing price.

Kaye Edward M. MD, the Director of Cytokinetics Incorporated, sale 20,000 shares at $30.00 during a trade that took place back on Oct 05, which means that Kaye Edward M. MD is holding 0 shares at $600,000 based on the most recent closing price.

Stock Fundamentals for CYTK

Current profitability levels for the company are sitting at:

  • -367.97 for the present operating margin

The net margin for Cytokinetics Incorporated stands at -452.93. The total capital return value is set at -102.20, while invested capital returns managed to touch -130.67. Equity return is now at value 363.30, with -58.10 for asset returns.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

When we switch over and look at the enterrpise to sales, we see a ratio of 19.42, with the company’s debt to enterprise value settled at 0.26. The receivables turnover for the company is 4.50 and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.98.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Important Earnings

Insider Watchlist

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.